ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Diagnosis, Treatment for Patient with Psoriasis, Fever, Bloating, and Rash

Jared H. Brock, BS, Blaine M. Hannafin, MD, RDMS, & Frank Lovecchio, DO, MPH  |  October 1, 2014

A 65-year-old man presents with symptoms of erythrodermic psoriasis flare

Filed under:ConditionsOther Rheumatic ConditionsPsoriatic Arthritis Tagged with:Diagnosisdruginfliximabpsoriatic arthritisrashrheumatologistrheumatology

Joint Smart Coalition Takes on Psoriasis in New York City

Richard Quinn  |  December 13, 2013

The Arthritis Foundation and the National Psoriasis Foundation launched the Joint Smart Coalition to focus on patient education, resources, and outreach. At a coalition-sponsored community-outreach event at Queens College in Flushing, N.Y.,  attendees were provided information on setting goals, stretching techniques, easy exercises, treatment options, and tips for a healthy lifestyle.  (posted Dec. 13)

Filed under:Uncategorized Tagged with:Arthritis FoundationNational Psoriasis FoundationNew York Citypatient educationPsoriasis

Susceptibility Loci Shed Light on Fundamental Pathways of Psoriasis

Lara C. Pullen, PhD  |  April 26, 2013

Investigators have described 15 new psoriasis susceptibility loci. The loci highlight the importance of the skin in both acquired and innate host defense and identify the innate immune response as a key factor in psoriasis.

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Genetic researchPsoriasis

Secrets & Pearls of Rheumatology at ACR Convergence 2025

Mithu Maheswaranathan, MD  |  November 12, 2025

Two clinical diagnosticians presented their pearls of wisdom for clinical rheumatologists to take forward when managing patients from the clinics to the hospital wards.

Filed under:ACR ConvergenceMeeting ReportsMyositisOther Rheumatic ConditionsSjögren’s DiseaseSystemic Lupus ErythematosusVasculitis Tagged with:ACR Convergence 2025ACR Convergence 2025 - LNconnective tissue diseaseLupusLupus nephritismyositisRaynaud’s phenomenonRheumatic DiseaseSjögren's Diseasesystemic lupus erythematosus (SLE)

Emerging Treatments in Psoriatic Arthritis

Ruth Jessen Hickman, MD  |  October 29, 2025

At a scientific session of ACR Convergence 2025, Alexis Ogdie, MD, discussed new and forthcoming treatments for psoriatic arthritis.

Filed under:ACR ConvergenceBiologics/DMARDsDrug UpdatesMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2025ACR Convergence 2025 - PsABiologics

What’s New in Psoriatic Arthritis?

David Pisetsky, MD, PhD  |  October 28, 2025

Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”

Filed under:ACR ConvergenceConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2025ACR Convergence 2025 - PsAAxial Psoriatic Arthritis (axPsA)inflammatory bowel disease (IBD)Obesity

The 2025 ACR Awards of Distinction

Patrice Fusillo  |  October 25, 2025

The ACR honors excellence in rheumatology. Meet the 2025 Awards of Distinction recipients, ACR Masters & Distinguished Fellows recognized at ACR Convergence 2025.

Filed under:ACR ConvergenceAwardsCareerMeeting Reports Tagged with:ACR Convergence 2025ACR MastersDistinguished Clinical Investigatordistinguished fellowHenry Kunkel Young Investigator AwardhonorsPresidential Gold Medal

Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis Released

Deborah Levenson  |  October 8, 2025

New global criteria for pediatric CNO aim to boost research & improve care for this rare autoinflammatory bone disease.

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceOsteoarthritis and Bone DisordersPediatric ConditionsResearch Rheum Tagged with:autoinflammatory diseasebone painchronic nonbacterial osteomyelitisClassification CriteriaimagingPediatrics

Oral Treatment for PsA Inches Closer to FDA Approval

Michele B. Kaufman, PharmD, BCGP  |  September 15, 2025

The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:deucravacitinibU.S. Food and Drug Administration (FDA)

Finding the Panacea: The Management of Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  July 16, 2025

In a session at EULAR 2025, Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsPsoriatic Arthritis Tagged with:Axial Psoriatic Arthritis (axPsA)EULAR 2025PsAPsA Resource Centerpsoriatic arthritisskin

  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 56
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences